X4 Pharmaceuticals Profit Margin

X4 Pharmaceuticals (XFOR) currently reports a profit margin of -474.74% as of September 2026. That compares with -279.86% in the prior-year period — down 69.6% year over year. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore X4 Pharmaceuticals's profit margin history and peer comparisons.

X4 Pharmaceuticals's profit margin decreased from -279.86% to -474.74% — a 69.6% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

X4 Pharmaceuticals's profit margin of -474.74% is lower than the Healthcare sector average of 17.63%. That is roughly 2793.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but X4 Pharmaceuticals's current -474.74% should be judged against Healthcare norms (sector average: 17.63%) and against XFOR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -474.74%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for X4 Pharmaceuticals, and consider following XFOR for alerts when major investors trade the stock.